2nd Circ. Upholds Merck Win In Bellwether Fosamax Trial
The Second Circuit denied a plaintiff's bid for a retrial Wednesday in a bellwether case in multidistrict litigation claiming Merck & Co.'s bone drug Fosamax causes jaw deterioration, ruling a lower...To view the full article, register now.
Already a subscriber? Click here to view full article